As Sage Therapeutics Inc. contemplates its path forward after rejecting a buyout offer from Biogen, its top executive ...

Some of Massachusetts’ largest life sciences employers, as well as smaller biotechs, increased their headcount in 2024, ...

High-rolling investors have positioned themselves bullish on Biogen BIIB, and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking of ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...

Biogen has bolstered its pipeline by licensing ex-US rights to a drug for Dravet syndrome – a rare form of epilepsy – from ...

Zorevunersen is intended for treating Dravet syndrome. Credit: Maks_lab/Shutterstock. Biogen has entered a collaboration with Stoke Therapeutics to develop and and commercialise zorevunersen to treat ...

Biogen's pipeline has faced setbacks, including the discontinuation of SAGE-324 for essential tremor following disappointing Phase 2 results. However, the company maintains several promising ...

Biogen's pipeline has faced setbacks, including the discontinuation of SAGE-324 for essential tremor following disappointing Phase 2 results. However, the company maintains several promising ...

He said about the same when Biogen put in the offer to buy Sage. Biogen shares were mostly unchanged in morning trading Tuesday. Last spring, Stoke released more data from a small study of ...

Biogen’s leadership has said they aren’t eager to deal, but turns out Stoke Therapeutics had a little something in its rare disease catalog that prompted Biogen to strike. The companies will work on a ...

Biogen's strategic missteps, including the failed Sage Therapeutics acquisition, underscore a lack of innovation and direction, leading to a "sell" rating. Despite being forewarned, Wall Street ...